Skip to main content

Table 1 Patient characteristics at index date, n (%)

From: Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis

Characteristic Patients (N = 330)
Sex
 Female 222 (67%)
 Male 108 (33%)
Age at index
 1–4 years 42 (13%)
 5–9 years 77 (23%)
 10–14 years 129 (39%)
 15–17 years 82 (25%)
Indication*
 Juvenile idiopathic arthritis 316 (96%)
 Psoriatic arthritis 10 (3%)
 Ankylosing spondylitis 3 (1%)
Region
 Quebec 118 (36%)
 Ontario 110 (33%)
 Alberta 50 (15%)
 East 33 (10%)
 British Columbia 15 (5%)
 Prairies 3* (1%)
Payer
 PDP 286 (87%)
 OPDP 28 (8%)
 RAMQ 16 (5%)
  1. * Indications were inferred using an algorithm developed by IQVIA, which uses a patient’s drug history [7, 8, 30]
  2. Groups with less than 6 patients/claims were adjusted to 3 to maintain privacy
  3. PDP, IQVIA Private Drug Plan; OPDP, Ontario Public Drug Plans; RAMQ, Quebec Public Drug Plan, Régie de l’assurance maladie du Québec